1
|
Rahimnia R, Akbari MR, Yasseri AF, Taheri D, Mirzaei A, Ghajar HA, Farashah PD, Baghdadabad LZ, Aghamir SMK. The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study. Sci Rep 2023; 13:18940. [PMID: 37919464 PMCID: PMC10622576 DOI: 10.1038/s41598-023-46118-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 10/27/2023] [Indexed: 11/04/2023] Open
Abstract
Ganoderma lucidum polysaccharide is the most widely used complementary therapy in cancer. The present study aims to investigate the possible interaction between Ganoderma lucidum polysaccharide and Docetaxel (a chemotherapy drug) and the first-line medication for prostate cancer treatment (Flutamide) and sensitizing the cells to these treatments. The cytotoxic effects of Ganoderma lucidum polysaccharide in combination with Docetaxel and Flutamide on prostate cancer cells were investigated by the MTT test, Hoechst staining, and flow cytometry. In addition, the expression of genes related to apoptosis, angiogenesis, Epithelial-Mesenchymal Transition pathway (EMT), and prostate cancer biomarkers by Real-Time PCR was investigated. The results demonstrated that IC50 values for Ganoderma lucidum polysaccharide (30 μM and 20 μM), Docetaxel (10 μM and 5 μM), and Flutamide (20 μM and 12 μM) with MTT were confirmed by flow cytometry in a dose and time-dependent manner. Regarding the high efficacy of Ganoderma lucidum polysaccharide in combination with Flutamide and Docetaxel, 10 μM and 5 μM Flutamide were used instead of 20 μM and 12 μM and 5 μM and 2 μM Docetaxel was used instead of 10 μM and 5 μM in PC3 and LNCap, respectively. Moreover, for the first time, it was shown that Ganoderma lucidum polysaccharide alone and in combination with Docetaxel and Flutamide significantly augmented apoptosis, reduced cell migration and colonization, and downregulated expression of KLK2 and EMT pathway genes in both PC3 and LNCap cell line (P < 0.01). Ganoderma lucidum polysaccharide synergistically increased the effect of Docetaxel and Flutamide and increased the sensitivity of the prostate cancer cell lines to these drugs. Therefore, it may provide a new therapeutic strategy against prostate cancer.
Collapse
Affiliation(s)
- Ramin Rahimnia
- Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohmammad Reza Akbari
- Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Canada
- Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada
| | | | - Diana Taheri
- Isfahan Kidney Disease Research Center, Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Akram Mirzaei
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | | | | | | | | |
Collapse
|
2
|
Afrouzian M, Kozakowski N, Liapis H, Broecker V, Truong L, Avila-Casado C, Regele H, Seshan S, Ambruzs JM, Farris AB, Buob D, Chander PN, Cheraghvandi L, Clahsen-van Groningen MC, de Almeida Araujo S, Baydar DE, Formby M, Ljubanovic DG, Hernandez LH, Honsova E, Mohamed N, Ozluk Y, Rabant M, Royal V, Stevenson HL, Toniolo MF, Taheri D. Corrigendum: Thrombotic Microangiopathy in the Renal Allograft: Results of the TMA Banff Working Group Consensus on Pathologic Diagnostic Criteria. Transpl Int 2023; 36:12047. [PMID: 37908678 PMCID: PMC10615063 DOI: 10.3389/ti.2023.12047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 09/26/2023] [Indexed: 11/02/2023]
Abstract
[This corrects the article DOI: 10.3389/ti.2023.11590.].
Collapse
Affiliation(s)
- Marjan Afrouzian
- Department of Pathology, John Sealy School of Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States
| | | | - Helen Liapis
- Nephrology Center, Ludwig Maximilian University of Munich, Munich, Germany
| | - Verena Broecker
- Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Luon Truong
- Department of Pathology and Genomic Medicine, The Houston Methodist Hospital, Houston, TX, United States
| | - Carmen Avila-Casado
- Laboratory Medicine Program, Toronto General Hospital, University Health Network (UHN), Toronto, ON, Canada
| | - Heinz Regele
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - Surya Seshan
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States
| | | | - Alton Brad Farris
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States
| | - David Buob
- Department of Pathology, Université de Sorbonne, Assistance Publique—Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | | | - Lukman Cheraghvandi
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States
| | - Marian C. Clahsen-van Groningen
- Department of Pathology and Clinical Bioinformatics, Erasmus University Center Rotterdam, Rotterdam, Netherlands
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany
| | - Stanley de Almeida Araujo
- Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Dilek Ertoy Baydar
- Department of Pathology, Koç University School of Medicine, Istanbul, Türkiye
| | - Mark Formby
- Department of Anatomical Pathology, NSW Health Pathology, Callaghan, NSW, Australia
- School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW, Australia
| | | | | | - Eva Honsova
- AeskuLab Pathology and Department of Pathology, Charles University, Prague, Czechia
| | - Nasreen Mohamed
- Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia
| | - Yasemin Ozluk
- Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - Marion Rabant
- Department of Pathology, Necker-Enfants Malades Hospital, Université Paris Cité, Paris, France
| | - Virginie Royal
- Department of Pathology, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada
| | - Heather L. Stevenson
- Department of Pathology, John Sealy School of Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States
| | - Maria Fernanda Toniolo
- Kidney Pancreas Transplantation, Instituto de Nefrología-Nephrology, Buenos Aires, Argentina
| | - Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
- Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
3
|
Afrouzian M, Kozakowski N, Liapis H, Broecker V, Truong L, Avila-Casado C, Regele H, Seshan S, Ambruzs JM, Farris AB, Buob D, Chander PN, Cheraghvandi L, Clahsen-van Groningen MC, de Almeida Araujo S, Baydar DE, Formby M, Ljubanovic DG, Hernandez LH, Honsova E, Mohamed N, Ozluk Y, Rabant M, Royal V, Stevenson HL, Toniolo MF, Taheri D. Corrigendum: Delphi: A Democratic and Cost-Effective Method of Consensus Generation in Transplantation. Transpl Int 2023; 36:12046. [PMID: 37908677 PMCID: PMC10615058 DOI: 10.3389/ti.2023.12046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 09/27/2023] [Indexed: 11/02/2023]
Abstract
[This corrects the article DOI: 10.3389/ti.2023.11589.].
Collapse
Affiliation(s)
- Marjan Afrouzian
- Department of Pathology, John Sealy School of Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States
| | | | - Helen Liapis
- Nephrology Center, Ludwig Maximilian University of Munich, Munich, Germany
| | - Verena Broecker
- Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Luan Truong
- Department of Pathology and Genomic Medicine, The Houston Methodist Hospital, Houston, TX, United States
| | - Carmen Avila-Casado
- Laboratory Medicine Program, Toronto General Hospital, University Health Network (UHN), Toronto, ON, Canada
| | - Heinz Regele
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - Surya Seshan
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States
| | | | - Alton Brad Farris
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States
| | - David Buob
- Department of Pathology, Université de Sorbonne, Assistance Publique—Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | | | - Lukman Cheraghvandi
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States
| | - Marian C. Clahsen-van Groningen
- Department of Pathology and Clinical Bioinformatics, Erasmus University Center Rotterdam, Rotterdam, Netherlands
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany
| | - Stanley de Almeida Araujo
- Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Dilek Ertoy Baydar
- Department of Pathology, Koç University School of Medicine, Istanbul, Türkiye
| | - Mark Formby
- Department of Anatomical Pathology, NSW Health Pathology, Callaghan, NSW, Australia
- School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW, Australia
| | | | | | - Eva Honsova
- AeskuLab Pathology and Department of Pathology, Charles University, Prague, Czechia
| | - Nasreen Mohamed
- Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia
| | - Yasemin Ozluk
- Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - Marion Rabant
- Department of Pathology, Necker-Enfants Malades Hospital, Université de Paris Cité, Paris, France
| | - Virginie Royal
- Department of Pathology, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada
| | - Heather L. Stevenson
- Department of Pathology, John Sealy School of Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States
| | - Maria Fernanda Toniolo
- Kidney Pancreas Transplantation, Instituto de Nefrología-Nephrology, Buenos Aires, Argentina
| | - Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
- Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
4
|
Afrouzian M, Kozakowski N, Liapis H, Broecker V, Truong L, Avila-Casado C, Regele H, Seshan S, Ambruzs JM, Farris AB, Buob D, Chander PN, Cheraghvandi L, Clahsen-van Groningen MC, de Almeida Araujo S, Ertoy Baydar D, Formby M, Galesic Ljubanovic D, Herrera Hernandez L, Honsova E, Mohamed N, Ozluk Y, Rabant M, Royal V, Stevenson HL, Toniolo MF, Taheri D. Delphi: A Democratic and Cost-Effective Method of Consensus Generation in Transplantation. Transpl Int 2023; 36:11589. [PMID: 37680647 PMCID: PMC10481336 DOI: 10.3389/ti.2023.11589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Accepted: 08/09/2023] [Indexed: 09/09/2023]
Abstract
The Thrombotic Microangiopathy Banff Working Group (TMA-BWG) was formed in 2015 to survey current practices and develop minimum diagnostic criteria (MDC) for renal transplant TMA (Tx-TMA). To generate consensus among pathologists and nephrologists, the TMA BWG designed a 3-Phase study. Phase I of the study is presented here. Using the Delphi methodology, 23 panelists with >3 years of diagnostic experience with Tx-TMA pathology listed their MDC suggesting light, immunofluorescence, and electron microscopy lesions, clinical and laboratory information, and differential diagnoses. Nine rounds (R) of consensus resulted in MDC validated during two Rs using online evaluation of whole slide digital images of 37 biopsies (28 TMA, 9 non-TMA). Starting with 338 criteria the process resulted in 24 criteria and 8 differential diagnoses including 18 pathologic, 2 clinical, and 4 laboratory criteria. Results show that 3/4 of the panelists agreed on the diagnosis of 3/4 of cases. The process also allowed definition refinement for 4 light and 4 electron microscopy lesions. For the first time in Banff classification, the Delphi methodology was used to generate consensus. The study shows that Delphi is a democratic and cost-effective method allowing rapid consensus generation among numerous physicians dealing with large number of criteria in transplantation.
Collapse
Affiliation(s)
- Marjan Afrouzian
- Department of Pathology, John Sealy School of Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States
| | | | - Helen Liapis
- Nephrology Center, Ludwig Maximilian University of Munich, Munich, Germany
| | - Verena Broecker
- Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Luan Truong
- Department of Pathology and Genomic Medicine, The Houston Methodist Hospital, Houston, TX, United States
| | - Carmen Avila-Casado
- Laboratory Medicine Program, Toronto General Hospital, University Health Network (UHN), Toronto, ON, Canada
| | - Heinz Regele
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - Surya Seshan
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States
| | | | - Alton Brad Farris
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States
| | - David Buob
- Department of Pathology, Université de Sorbonne, Assistance Publique—Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | | | - Lukman Cheraghvandi
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States
| | - Marian C. Clahsen-van Groningen
- Department of Pathology and Clinical Bioinformatics, Erasmus University Center Rotterdam, Rotterdam, Netherlands
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany
| | - Stanley de Almeida Araujo
- Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Dilek Ertoy Baydar
- Department of Pathology, Koç University School of Medicine, Istanbul, Türkiye
| | - Mark Formby
- Department of Anatomical Pathology, NSW Health Pathology, Callaghan, NSW, Australia
- School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW, Australia
| | | | | | - Eva Honsova
- AeskuLab Pathology and Department of Pathology, Charles University, Prague, Czechia
| | - Nasreen Mohamed
- Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia
| | - Yasemin Ozluk
- Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - Marion Rabant
- Department of Pathology, Necker-Enfants Malades Hospital, Université de Paris Cité, Paris, France
| | - Virginie Royal
- Department of Pathology, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada
| | - Heather L. Stevenson
- Department of Pathology, John Sealy School of Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States
| | - Maria Fernanda Toniolo
- Kidney Pancreas Transplantation, Instituto de Nefrología-Nephrology, Buenos Aires, Argentina
| | - Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
- Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
5
|
Afrouzian M, Kozakowski N, Liapis H, Broecker V, Truong L, Avila-Casado C, Regele H, Seshan S, Ambruzs JM, Farris AB, Buob D, Chander PN, Cheraghvandi L, Clahsen-van Groningen MC, de Almeida Araujo S, Ertoy Baydar D, Formby M, Galesic Ljubanovic D, Herrera Hernandez L, Honsova E, Mohamed N, Ozluk Y, Rabant M, Royal V, Stevenson HL, Toniolo MF, Taheri D. Thrombotic Microangiopathy in the Renal Allograft: Results of the TMA Banff Working Group Consensus on Pathologic Diagnostic Criteria. Transpl Int 2023; 36:11590. [PMID: 37680648 PMCID: PMC10481335 DOI: 10.3389/ti.2023.11590] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Accepted: 08/09/2023] [Indexed: 09/09/2023]
Abstract
The Banff community summoned the TMA Banff Working Group to develop minimum diagnostic criteria (MDC) and recommendations for renal transplant TMA (Tx-TMA) diagnosis, which currently lacks standardized criteria. Using the Delphi method for consensus generation, 23 nephropathologists (panelists) with >3 years of diagnostic experience with Tx-TMA were asked to list light, immunofluorescence, and electron microscopic, clinical and laboratory criteria and differential diagnoses for Tx-TMA. Delphi was modified to include 2 validations rounds with histological evaluation of whole slide images of 37 transplant biopsies (28 TMA and 9 non-TMA). Starting with 338 criteria in R1, MDC were narrowed down to 24 in R8 generating 18 pathological, 2 clinical, 4 laboratory criteria, and 8 differential diagnoses. The panelists reached a good level of agreement (70%) on 76% of the validated cases. For the first time in Banff classification, Delphi was used to reach consensus on MDC for Tx-TMA. Phase I of the study (pathology phase) will be used as a model for Phase II (nephrology phase) for consensus regarding clinical and laboratory criteria. Eventually in Phase III (consensus of the consensus groups) and the final MDC for Tx-TMA will be reported to the transplantation community.
Collapse
Affiliation(s)
- Marjan Afrouzian
- Department of Pathology, John Sealy School of Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States
| | | | - Helen Liapis
- Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, United States
- Department of Nephrology, Ludwig Maximilian University, Munich, Germany
| | - Verena Broecker
- Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Luon Truong
- Department of Pathology, The Houston Methodist Hospital, Houston, TX, United States
| | - Carmen Avila-Casado
- Laboratory Medicine Program, University Health Network (UHN), Toronto, ON, Canada
| | - Heinz Regele
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - Surya Seshan
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States
| | | | - Alton Brad Farris
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States
| | - David Buob
- Department of Pathology, Université de Sorbonne, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | | | - Lukman Cheraghvandi
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States
| | - Marian C Clahsen-van Groningen
- Department of Pathology and Clinical Bioinformatics, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany
| | - Stanley de Almeida Araujo
- Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Dilek Ertoy Baydar
- Department of Pathology, School of Medicine, Koç University, Sarıyer, Türkiye
| | - Mark Formby
- Department of Anatomical Pathology, NSW Health Pathology, Callaghan, NSW, Australia
- School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia
| | | | | | - Eva Honsova
- AeskuLab Pathology and Department of Pathology, Charles University, Prague, Czechia
| | - Nasreen Mohamed
- Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia
| | - Yasemin Ozluk
- Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - Marion Rabant
- Department of Pathology, Necker-Enfants Malades Hospital, Université Paris Cité, Paris, France
| | - Virginie Royal
- Department of Pathology, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada
| | - Heather L Stevenson
- Department of Pathology, John Sealy School of Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States
| | - Maria Fernanda Toniolo
- Kidney Pancreas Transplantation, Instituto de Nefrología-Nephrology, Buenos Aires, Argentina
| | - Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
6
|
Kafi F, Mortazavi M, Pouramini A, Dolatkhah S, Kaleidari B, Taheri D. Secondary oxalate nephropathy and impact of high-dose vitamin C intake for COVID-19 prevention on a patient with Roux-en-Y gastric bypass: A case report. Clin Case Rep 2023; 11:e7020. [PMID: 36911630 PMCID: PMC9992142 DOI: 10.1002/ccr3.7020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 02/04/2023] [Accepted: 02/15/2023] [Indexed: 03/11/2023] Open
Abstract
The current study is important in informing clinicians about the possibility of concurrent oxalate nephropathy caused by Roux-en-Y gastric bypass, high oxalate materials, and high-dose vitamin C intake for COVID-19 prevention.
Collapse
Affiliation(s)
- Fatemeh Kafi
- Department of Pathology, Isfahan Kidney Diseases Research Center Isfahan University of Medical Sciences Isfahan Iran.,Urology Research Center Tehran University of Medical Sciences Tehran Iran
| | - Mojgan Mortazavi
- Isfahan Kidney Diseases Research Center Isfahan University of Medical Sciences Isfahan Iran
| | - Alireza Pouramini
- Department of Pathology, Isfahan Kidney Diseases Research Center Isfahan University of Medical Sciences Isfahan Iran.,Urology Research Center Tehran University of Medical Sciences Tehran Iran
| | | | - Behrouz Kaleidari
- Alzahra Hospital Isfahan University of Medical Sciences Isfahan Iran
| | - Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center Isfahan University of Medical Sciences Isfahan Iran.,Urology Research Center Tehran University of Medical Sciences Tehran Iran
| |
Collapse
|
7
|
Taheri D, Jahanshahi F, Khajavi A, Kafi F, Pouramini A, Farsani RM, Alizadeh Y, Akbarzadeh M, Reis LO, Khatami F, Aghamir SMK. The Impact of Covid-19 Pandemic on Genitourinary Cancers Stage and Grade. Clin Genitourin Cancer 2023; 21:84-90. [PMID: 36517394 PMCID: PMC9684093 DOI: 10.1016/j.clgc.2022.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2022] [Revised: 11/19/2022] [Accepted: 11/20/2022] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Our study aims to evaluate the impact of the COVID-19 pandemic on the number of uro-oncological surgeries (cystectomy, nephrectomy, prostatectomy, orchiectomy, and transurethral resection of bladder tumor (TURBT)) and pathological staging and grading. MATERIALS AND METHODS The present study is a retrospective study on patients with genitourinary cancers treated from 2018 to 2021 in a referral tertiary center. The data were obtained from the hospital records with lengths of 22 and 23 months, labeled hereafter as non-COVID and COVID pandemic, respectively (2018/3/21-2020/1/20 and 2020/1/21-2021/12/21). The total number of registered patients, gender, age, stage, and grade were compared in the targeted periods. Moreover, all the pathologic slides were reviewed by an expert uropathologist before enrolling in the study. The continuous and discrete variables are reported as mean (standard deviation (SD)) and number (percent) and the χ2 test for the comparison of the discrete variables' distribution. RESULTS In this study total number of 2077 patients were enrolled. The number of procedures performed decreased during the Covid pandemic. The tumors' distribution stage and grade and patients' baseline characteristics were not significantly different in non-COVID and COVID pandemic periods for Radical Nephrectomy, Radical Cystectomy, Radical Prostatectomy, and orchiectomy. For TURBT only, the tumor stage was significantly different (P-value<.001) from the higher stages in the COVID pandemic period. CONCLUSION Among urinary tract cancers, staging of bladder cancer and TURBT are mainly impacted by the COVID-19 pandemic with higher stages compared to the non-COVID period. We evaluate the impact of the COVID-19 pandemic on the number of uro-oncological surgeries based on pathological staging and grading. Total number of 2077 patients were enrolled. Among urinary tract cancers, staging of bladder cancer and TURBT are mainly impacted by the COVID-19 pandemic with higher stages compared to the non-COVID period.
Collapse
Affiliation(s)
- Diana Taheri
- Isfahan Kidney Disease Research Center, Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran,Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Jahanshahi
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran,Research Committee Member, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Alireza Khajavi
- Student Research Committee, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Fatemeh Kafi
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Alireza Pouramini
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Reza M. Farsani
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Maryam Akbarzadeh
- Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands
| | - Leonardo O. Reis
- UroScience and Department of Surgery (Urology), School of Medical Sciences, University of Campinas, Unicamp, and Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, São Paulo, Brazil
| | - Fatemeh Khatami
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | | |
Collapse
|
8
|
Asgari F, Golmohammadi P, Taheri D, Kazem Aghamir SM. 23-Year-Old Male with Testis Cancer with Spontaneous Ruptured Teratocarcinoma and No History of Trauma: A Case Report. Case Rep Oncol 2023; 16:262-266. [PMID: 37123610 PMCID: PMC10134056 DOI: 10.1159/000530502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 03/21/2023] [Indexed: 05/02/2023] Open
Abstract
Teratocarcinoma is one type of testis cancer that can be represented in the youth population and usually shows itself with swelling of the testis and edema and a rise of BHCG and alpha-fetoprotein, but spontaneous rupture is a rare manifestation. A 23-year-old man was referred to the Sina Hospital with complaints of testis pain and swelling. Laboratory findings were alpha f.p more than 2,000, BHCG titer 255.21, and LDH 504. Sonography findings showed the right testis had been detected with a heterogeneous mass with vascularity and cystic area with microcalcification, measuring 76*69 mm. During surgery, we faced rupture tumor that was unusual and rare. The radical orchidectomy was done successfully without any complications. After the surgery, pathology showed teratocarcinoma of the right testis, and a 6-month observation and follow-up were done without any complication.
Collapse
Affiliation(s)
- Fardin Asgari
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Pedram Golmohammadi
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Diana Taheri
- Isfahan Kidney Disease Research Center, Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
| | | |
Collapse
|
9
|
Shahidi S, Dolatkhah S, Mortazavi M, Atapour A, Aghaaliakbari F, Meamar R, Badri M, Taheri D. An Epidemiological Survey on Kidney Stones and Related Risk Factors in the Iranian Community. ACTA 2022. [DOI: 10.18502/acta.v60i5.9558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Increasing number of patients with kidney stones is a major worldwide concern that needs more attention for recognizing the disease in order to set up suitable prevention systems. In this study, we aimed to assess the prevalence and related risk factors of kidney stones in our local area (Isfahan, Iran). In 2011, we celebrated World Kidney Day (WKD) with several training programs for informing people about kidney diseases. A questionnaire containing demographic data, past medical history, and familial and self-history of kidney disease was fulfilled by each individual who participated in WKD. Blood pressure and body mass index (BMI) were also measured using standard methods. Statistical analysis with SPSS-20 software was done. 556 participants with a mean age of 44.69±15.32 were included in the study, of which 107 cases (19.2%) with a mean age of 50.24±12.33 had a kidney stone, and 449 cases (80.8%) with a mean age of 44.69±15.32 had no history of kidney stone. There were no significant differences between those with and without kidney stones regarding sex (P=0.176), type of daily work (P=0.91), diabetes mellitus (P=0.64), and place of living (urban versus rural) (P=0.92) and BMI (P=0.26). However, there were differences between groups regarding age (P˂0.001), Hypertension (HTN) (P=001), Cardiovascular disease (CVD) (P=0.02), and familial history of kidney stone (P˂0.001). Out of 107 patients with kidney stones, the mean number of urinary excretion of stones was 2.56±2.98. We found a greater prevalence of kidney stones in our local area compared with data from other research studies. Despite some previous studies, comparison of people with and without kidney stones did not reveal differences in the prevalence of DM, type of daily work (low activity versus high activity), and obesity but differences in the field of HTN and CVD were seen.
Collapse
|
10
|
Rodriguez Pena MDC, Springer SU, Taheri D, Li L, Tregnago AC, Eich ML, Eltoum IEA, VandenBussche CJ, Papadopoulos N, Kinzler KW, Vogelstein B, Netto GJ. Correction to: Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Arch 2022; 480:719. [PMID: 35178604 DOI: 10.1007/s00428-022-03292-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Maria Del Carmen Rodriguez Pena
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.,Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, 21231, USA
| | - Simeon U Springer
- The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD, 21231, USA.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Diana Taheri
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, 21231, USA.,Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Lu Li
- The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD, 21231, USA.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Aline C Tregnago
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, 21231, USA
| | - Marie-Lisa Eich
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.,Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, 21231, USA
| | - Isam-Eldin A Eltoum
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | | | - Nickolas Papadopoulos
- The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD, 21231, USA.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Kenneth W Kinzler
- The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD, 21231, USA.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Bert Vogelstein
- The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD, 21231, USA.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - George J Netto
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA. .,Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, 21231, USA.
| |
Collapse
|
11
|
Taheri D, Roohani E, Izadpanahi MH, Dolatkhah S, Aghaaliakbari F, Daneshpajouhnejad P, Gharaati MR, Mazdak H, Fesharakizadeh S, Beinabadi Y, Kazemi R, Rahbar M. Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population. J Res Med Sci 2021; 26:46. [PMID: 34484378 PMCID: PMC8384007 DOI: 10.4103/jrms.jrms_311_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Revised: 03/26/2020] [Accepted: 03/13/2021] [Indexed: 11/08/2022]
Abstract
Background: Considering the great variations in the reported prevalence of prostate cancer across the world possibly due to different genetic and environmental backgrounds, we aimed to determine the expression pattern and the diagnostic utility of α-methylacyl coenzyme A racemase (AMACR) among Iranian patients with prostate adenocarcinoma. Materials and Methods: In this cross-sectional study, formalin-fixed paraffin-embedded tissues of 58 patients with a definitive pathologic diagnosis of prostatic adenocarcinoma were evaluated. The expression of AMACR, intensity, and extensity of its staining was determined in selected samples by immunohistochemical technique. Results: AMACR expression was significantly higher in neoplastic compared to normal tissue (P < 0.05). The expression of AMACR was significantly associated with the age of the patients (P = 0.04). The intensity of the staining was associated with the grade of the prostate adenocarcinoma (P = 0.04). There was no significant relationship between AMACR expression and perineural invasion. The sensitivity, specificity, positive predictive value, and negative predictive value of AMACR were 90%, 96%, 96%, and 90%, respectively. Conclusion: Findings from our study indicate that AMACR could be used as a diagnostic tool for the diagnosis of prostate adenocarcinoma. However, due to false-positive staining in the mimicker of prostatic adenocarcinoma, it is recommended to use it in combination with basal cell markers.
Collapse
Affiliation(s)
- Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Elham Roohani
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Hossein Izadpanahi
- Department of Urology, Isfahan Urology and Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | | | - Parnaz Daneshpajouhnejad
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.,Student Research Committee, Isfahan Medical Students' Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Reza Gharaati
- Department of Urology, Isfahan Urology and Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Hamid Mazdak
- Department of Urology, Isfahan Urology and Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | | | - Reza Kazemi
- Department of Urology, Isfahan Urology and Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mahtab Rahbar
- Department of Pathology, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
12
|
Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Takao T, Yamaguchi S, Fushimi H, Yoshimura K, Uemura H, Netto GJ, Nonomura N. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. Int J Mol Sci 2020; 21:E5390. [PMID: 32751328 PMCID: PMC7432817 DOI: 10.3390/ijms21155390] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 07/20/2020] [Accepted: 07/27/2020] [Indexed: 12/30/2022] Open
Abstract
Enfortumab vedotin is a novel antibody-drug conjugate targeting Nectin-4, which is highly expressed in urothelial carcinoma. However, the expression status of Nectin-4 in upper tract urothelial carcinoma (UTUC) remains unclear. The relationship between Nectin-4 and Programmed Death Ligand 1 (PD-L1) in UTUC is also ambiguous. We performed immunohistochemical analysis of 99 UTUC tissue microarray to assess the expression of Nectin-4 and PD-L1 in UTUC. Nectin-4-positivity was detected in 65 (65.7%) samples, and PD-L1 was detected in 24 (24.2%) samples. There was no correlation between the expression of Nectin-4 and PD-L1. Patients with strong Nectin-4-expressing tumors had a significantly higher risk of progression (p = 0.031) and cancer-specific mortality (p = 0.036). Strong Nectin-4 expression was also an independent predictor of disease progression in the high-risk group (pT3 ≤ or presence of lymphovascular invasion or lymph node metastasis) (Hazard ratio, 3.32 [95% confidence interval, 1.20-7.98; p = 0.027]). In conclusion, we demonstrated that Nectin-4 expression rate in UTUC was 65.7% and independent of PD-L1 expression. Strong Nectin-4 expression was associated with worse progression-free survival in high-risk UTUC. These findings suggested that enfortumab vedotin may be effective in a broad range of patients with UTUC, regardless of PD-L1 expression.
Collapse
Affiliation(s)
- Eisuke Tomiyama
- Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; (E.T.); (T.K.); (K.H.); (A.K.); (T.U.); (M.U.); (N.N.)
| | - Kazutoshi Fujita
- Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; (E.T.); (T.K.); (K.H.); (A.K.); (T.U.); (M.U.); (N.N.)
- Department of Urology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Sayama, Osaka 589-8511, Japan; (E.B.); (K.Y.); (H.U.)
| | - Maria Del Carmen Rodriguez Pena
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233-7331, USA; (M.D.C.R.P.); (G.J.N.)
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
- Department of Pathology, Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran;
| | - Eri Banno
- Department of Urology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Sayama, Osaka 589-8511, Japan; (E.B.); (K.Y.); (H.U.)
| | - Taigo Kato
- Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; (E.T.); (T.K.); (K.H.); (A.K.); (T.U.); (M.U.); (N.N.)
- Department of Urological Immuno-Oncology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Koji Hatano
- Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; (E.T.); (T.K.); (K.H.); (A.K.); (T.U.); (M.U.); (N.N.)
| | - Atsunari Kawashima
- Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; (E.T.); (T.K.); (K.H.); (A.K.); (T.U.); (M.U.); (N.N.)
| | - Takeshi Ujike
- Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; (E.T.); (T.K.); (K.H.); (A.K.); (T.U.); (M.U.); (N.N.)
| | - Motohide Uemura
- Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; (E.T.); (T.K.); (K.H.); (A.K.); (T.U.); (M.U.); (N.N.)
- Department of Urological Immuno-Oncology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Tetsuya Takao
- Department of Urology, Osaka General Medical Center, Osaka 558 8558, Japan; (T.T.); (S.Y.)
| | - Seiji Yamaguchi
- Department of Urology, Osaka General Medical Center, Osaka 558 8558, Japan; (T.T.); (S.Y.)
| | - Hiroaki Fushimi
- Department of Pathology, Osaka General Medical Center, Osaka 558 8558, Japan;
| | - Kazuhiro Yoshimura
- Department of Urology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Sayama, Osaka 589-8511, Japan; (E.B.); (K.Y.); (H.U.)
| | - Hirotsugu Uemura
- Department of Urology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Sayama, Osaka 589-8511, Japan; (E.B.); (K.Y.); (H.U.)
| | - George J. Netto
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233-7331, USA; (M.D.C.R.P.); (G.J.N.)
| | - Norio Nonomura
- Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; (E.T.); (T.K.); (K.H.); (A.K.); (T.U.); (M.U.); (N.N.)
| |
Collapse
|
13
|
Cocks M, Chaux A, Jenson EG, Miller JA, Rodriguez Pena MDC, Tregnago AC, Taheri D, Eich ML, Sharma R, Vang R, Netto GJ. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma. Virchows Arch 2020; 477:93-102. [PMID: 31993774 DOI: 10.1007/s00428-020-02759-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 12/31/2019] [Accepted: 01/21/2020] [Indexed: 12/31/2022]
Abstract
Vulvar squamous cell carcinoma accounts for 5% of cancers of the female genital tract. Current guidelines recommend wide local excision with negative surgical margins as the standard treatment. However, the extent of the tumor-free resection margin after wide local excision is still controversial in many cases. Drugs targeting immune checkpoints such as PD-1 or its ligand PD-L1 have potential clinical utility in these patients. We examined the expression of PD-L1 in tumor cells and immune cells, as well as the proportion of PD-1, CD8, and FOXP3 positive lymphocytes. Twenty-one cases of invasive vulvar squamous cell carcinomas were reviewed. Whole slides of representative formalin-fixed, paraffin-embedded archival material were used for analysis. Odds ratios (OR) and hazard ratios (HR) were used to estimate risk for disease recurrence, overall mortality, and cancer mortality. PD-L1 expression was found in 43% of tumor cells, with higher proportions in intratumoral (67%) and peritumoral (81%) immune cells. OR and HR for disease recurrence and cancer mortality were higher in tumors with higher CD8 expression. OR and HR for overall mortality were also higher in tumors with higher PD-L1 and CD8 expression. In conclusion, nearly half of cases were PD-L1 positive in tumor cells with over two-third of cases demonstrating PD-L1 positivity in immune cells. Immunohistochemical expression of PD-L1 and CD8 could be used to suggest higher risk of disease recurrence, overall mortality, and cancer mortality. Furthermore, our data contributes to the growing evidence that targeting the PD-1/PD-L1 pathway may be beneficial in vulvar squamous cell carcinomas.
Collapse
Affiliation(s)
- Margaret Cocks
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Alcides Chaux
- Department of Scientific Research, School of Postgraduate Studies, Norte University, Asunción, Paraguay
| | - Erik G Jenson
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - James A Miller
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Maria Del Carmen Rodriguez Pena
- Department of Pathology, The University of Alabama at Birmingham, West Pavilion P210, 619 19th Street, South Birmingham, AL, 35249-7331, USA
| | - Aline C Tregnago
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Diana Taheri
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
- Isfahan Kidney Diseases Research Center, Pathology, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran
| | - Marie-Lisa Eich
- Department of Pathology, The University of Alabama at Birmingham, West Pavilion P210, 619 19th Street, South Birmingham, AL, 35249-7331, USA
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - Rajni Sharma
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Russell Vang
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - George J Netto
- Department of Pathology, The University of Alabama at Birmingham, West Pavilion P210, 619 19th Street, South Birmingham, AL, 35249-7331, USA.
| |
Collapse
|
14
|
Eich M, Chaux A, Mendoza Rodriguez MA, Guner G, Taheri D, Rodriguez Pena MDC, Sharma R, Allaf ME, Netto GJ. Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma. Histopathology 2019; 76:423-432. [DOI: 10.1111/his.13987] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 09/02/2019] [Indexed: 12/28/2022]
Affiliation(s)
- Marie‐Lisa Eich
- Department of Pathology University of Alabama at Birmingham Birmingham AL USA
| | - Alcides Chaux
- Department of Scientific Research School of Postgraduate Studies Norte University Asunción Paraguay
| | | | - Gunes Guner
- Department of Pathology Johns Hopkins University Baltimore MD USA
| | - Diana Taheri
- Department of Pathology Johns Hopkins University Baltimore MD USA
- Department of Pathology Isfahan Kidney Disease Research Center Isfahan University of Medical Sciences Isfahan University of Medical Sciences Isfahan Iran
| | | | - Rajni Sharma
- Department of Pathology Johns Hopkins University Baltimore MD USA
| | - Mohamad E Allaf
- Department of Urology Johns Hopkins University Baltimore MD USA
| | - George J Netto
- Department of Pathology University of Alabama at Birmingham Birmingham AL USA
| |
Collapse
|
15
|
Eich ML, Rodriguez Pena MDC, Springer S, Taheri D, Tregnago AC, Salles DC, Bezerra SM, Cunha IW, Fujita K, Ertoy D, Bivalacqua TJ, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Netto GJ. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. Mod Pathol 2019; 32:1544-1550. [PMID: 31028363 PMCID: PMC6872189 DOI: 10.1038/s41379-019-0276-y] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 03/22/2019] [Accepted: 03/23/2019] [Indexed: 11/22/2022]
Abstract
Noninvasive approaches for early detection of bladder cancer are actively being investigated. We recently developed a urine- based molecular assay for the detection and surveillance of bladder neoplasms (UroSEEK). UroSEEK is designed to detect alterations in 11 genes that include most common genetic alterations in bladder cancer. In this study, we analyzed 527 cases, including 373 noninvasive and 154 invasive urothelial carcinomas of bladder from transurethral resections or cystectomies performed at four institutions (1991-2016). Two different mutational analysis assays of a representative tumor area were performed: first, a singleplex PCR assay for evaluation of the TERT promoter region (TERTSeqS) and second, a multiplex PCR assay using primers designed to amplify regions of interest of 10 (FGFR3, PIK3CA, TP53, HRAS, KRAS, ERBB2, CDKN2A, MET, MLL, and VHL) genes (UroSeqS). Overall, 92% of all bladder tumors were positive for at least one genetic alteration in the UroSEEK panel. We found TERT promoter mutations in 77% of low-grade noninvasive papillary carcinomas, with a relatively lower incidence of 65% in high-grade noninvasive papillary carcinomas and carcinomas in situ; p = 0.017. Seventy-two percent of pT1 and 63% of muscle-invasive bladder tumors harbored TERT promoter mutations with g.1295228C>T alteration being the most common in all groups. FGFR3 and PIK3CA mutations were more frequent in low-grade noninvasive papillary carcinomas compared with high-grade noninvasive papillary carcinomas and carcinomas in situ (p < 0.0001), while the opposite was true for TP53 (p < 0.0001). Significantly higher rates of TP53 and CDKN2A mutation rates (p = 0.005 and 0.035, respectively) were encountered in muscle-invasive bladder tumors compared with those of pT1 stage. The overwhelming majority of all investigated tumors showed at least one mutation among UroSEEK assay genes, confirming the comprehensive coverage of the panel and supporting its potential utility as a noninvasive urine-based assay.
Collapse
Affiliation(s)
- Marie-Lisa Eich
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, United States
| | | | - Simeon Springer
- Howard Hughes Medical Institute, Ludwig Cancer for Cancer Genetics and Therapeutics, Baltimore, United States,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, United States,Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | | | - Stephania Martins Bezerra
- Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil,Department of Pathology, Rede D’OR-São Luiz, Sao Paulo, Brazil
| | - Isabela W. Cunha
- Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil
| | | | - Dilek Ertoy
- Department of Pathology, Hacettepe University, Ankara, Turkey
| | | | - Cristian Tomasetti
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States,Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Cancer Center
| | - Nickolas Papadopoulos
- Howard Hughes Medical Institute, Ludwig Cancer for Cancer Genetics and Therapeutics, Baltimore, United States,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Ken W. Kinzler
- Howard Hughes Medical Institute, Ludwig Cancer for Cancer Genetics and Therapeutics, Baltimore, United States,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Bert Vogelstein
- Howard Hughes Medical Institute, Ludwig Cancer for Cancer Genetics and Therapeutics, Baltimore, United States,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - George J. Netto
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, United States
| |
Collapse
|
16
|
Taheri D, Dolatkhah S, Aghaaliakbari F, Beinabadi Y, Atapour A, Shahidi S. P213 The association between mononuclear inflammatory cells infiltration and histopathologic changes of acute renal allograft rejection; a local experience and review of literatures. Hum Immunol 2019. [DOI: 10.1016/j.humimm.2019.07.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Rodriguez Pena MDC, Chaux A, Eich ML, Tregnago AC, Taheri D, Borhan W, Sharma R, Rezaei MK, Netto GJ. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Arch 2019; 475:349-356. [DOI: 10.1007/s00428-019-02618-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Revised: 06/04/2019] [Accepted: 06/27/2019] [Indexed: 12/14/2022]
|
18
|
Eich ML, Chaux A, Guner G, Taheri D, Mendoza Rodriguez MA, Rodriguez Peña MDC, Baras AS, Hahn NM, Drake C, Sharma R, Bivalacqua TJ, Rezaei K, Netto GJ. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. Hum Pathol 2019; 89:24-32. [PMID: 31026471 DOI: 10.1016/j.humpath.2019.04.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 04/09/2019] [Accepted: 04/14/2019] [Indexed: 02/04/2023]
Abstract
Immunotherapy has gained significance in a variety of tumor types including advanced urothelial carcinoma. Noninvasive urothelial lesions have been treated with intravesical Bacillus-Calmette-Guerin (BCG) for decades. Given treatment failure in a subset of these tumors, ongoing clinical trials investigating the role of checkpoint inhibitors are actively pursued in this group of patients. The present study aims to delineate PD-L1, CD8, and FOXP3 expression in tumor microenvironment in non-muscle-invasive urothelial carcinoma samples obtained via sequential biopsies and to assess its potential role in predicting disease outcome. Cases with >1% and> 5% PD-L1 expression in tumor cells showed lower relative risk (RR) to recur at any subsequent biopsy compared with those with lower PD-L1 expression (RRs, 0.83 [P = .009] and 0.81 [P = .03], respectively). Cases with higher expression of FOXP3 in peritumoral lymphocytes were at lower risk for tumor grade progression at any biopsy (RR, 0.2; P = .02). Tumors with FOXP3/CD8 expression ratio of >1 in intratumoral lymphocytes had lower risk of grade progression (RR, 0.28; P = .04). Although higher number of FOXP3-, CD8-, and PD-L1-positive lymphocytes were encountered after BCG treatment, the findings did not reach statistical significance. In patients without BCG treatment, PD-L1 expression in tumor cells and peritumoral lymphocytes varied across serial biopsies, suggesting the need for additional approaches to assess eligibility for immunotherapy in non-muscle-invasive urothelial carcinoma patients.
Collapse
Affiliation(s)
- Marie-Lisa Eich
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35249, USA
| | - Alcides Chaux
- Department of Scientific Research, School of Postgraduate Studies, Norte University, 1614 Asunción, Paraguay
| | - Gunes Guner
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA
| | | | | | - Alexander S Baras
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA
| | - Noah M Hahn
- Department of Urology, Johns Hopkins University, Baltimore, MD 21231, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21231, USA
| | - Charles Drake
- Department of Urology, Johns Hopkins University, Baltimore, MD 21231, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21231, USA
| | - Rajni Sharma
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA
| | - Trinity J Bivalacqua
- Department of Urology, Johns Hopkins University, Baltimore, MD 21231, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21231, USA
| | - Katayoon Rezaei
- Department of Pathology, George Washington University, Washington, DC 20037, USA
| | - George J Netto
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35249, USA.
| |
Collapse
|
19
|
Dolatkhah S, Mirtalebi M, Daneshpajouhnejad P, Barahimi A, Mazdak H, Izadpanahi MH, Mohammadi M, Taheri D. Discrepancies Between Biopsy Gleason Score and Radical Prostatectomy Specimen Gleason Score: An Iranian Experience. Urol J 2019; 16:56-61. [PMID: 30345499 DOI: 10.22037/uj.v0i0.4174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
PURPOSE Considering the importance of treatment decisions for prostate cancer (PCa) and the utility of Gleason scoring system (GS) in this field, we aimed to assess the percent of agreement and disagreement between needle biopsy (NB) Gleason score and radical prostatectomy (RP) specimen Gleason score. MATERIALS AND METHODS In this retrospective study, consecutive patients with PCa, who underwent NB and subsequently RP were enrolled. GS of both NB and RP specimens were recorded for each patient. Patients were classified according to the GS as low-grade (? 3+3), intermediate-grade (3+4 and 4+3), and high-grade (GS?8-10). The levels of agreement and discrepancy of NB GS was compared to its corresponding RP GS using Kappa coefficient of agreement. Over-grading and under-grading of NB GS were also determined. RESULT A total of 100 embedded RP and corresponding NB were analyzed. The rate of discrepancy for group and individual scoring of GS was 41% and 56%, respectively. The rate of under and over-grading was 34% and 7%, respectively. Kappa value for group and individual scoring was .443 (95%CI: .313 - .573) and .411 (95%CI: .291 - .531), respectively. CONCLUSION The findings of our study indicate that though the agreement between NB GS and RP GS are fair to moderate, but the feature of discrepancy, i.e. under-grading in low and intermediate grades and over-grading in high grades of NB GS, could help us in making more appropriate clinical decision especially considering other biochemical and pathological factors such as the level of PSA or peri-neural invasion.
Collapse
Affiliation(s)
- Shahaboddin Dolatkhah
- Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
| | - Maryam Mirtalebi
- Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Parnaz Daneshpajouhnejad
- Student Research Committee, Isfahan Medical Students' Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Ahmadreza Barahimi
- Department of Medical Mycology, School of Medicine, Tarbiat Modares University, Tehran, Iran
| | - Hamid Mazdak
- Department of Urology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Hossein Izadpanahi
- Department of Urology, Isfahan Urology and Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mehrdad Mohammadi
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Diana Taheri
- Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
20
|
Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, Rodriguez Pena MDC, Wang Y, Kinde I, Ricardo BFP, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum Pathol 2018; 85:1-9. [PMID: 30447301 DOI: 10.1016/j.humpath.2018.10.033] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Revised: 10/25/2018] [Accepted: 10/31/2018] [Indexed: 02/07/2023]
Abstract
Activating mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the most common genetic alterations in urothelial carcinoma (UC) of the bladder and upper urinary tract. Although the cadherin 1 (CDH1) gene is commonly mutated in the clinically aggressive plasmacytoid variant of urothelial carcinoma (PUC), little is known about their TERT promoter mutation status. A retrospective search of our archives for PUC and UC with plasmacytoid and/or signet ring cell features (2007-2014) was performed. Ten specimens from 10 patients had archived material available for DNA analysis and were included in the study. Intratumoral areas of nonplasmacytoid histology were also evaluated when present. Samples were analyzed for TERT promoter mutations with Safe-SeqS, a sequencing error-reduction technology, and sequenced using a targeted panel of the 10 most commonly mutated genes in bladder cancer on the Illumina MiSeq platform. TERT promoter mutations were detected in specimens with pure and focal plasmacytoid features (6/10). Similar to conventional UC, the predominant mutation identified was g.1295228C>T. In heterogeneous tumors with focal variant histology, concordant mutations were found in plasmacytoid and corresponding conventional, glandular, or sarcomatoid areas. Co-occurring mutations in tumor protein p53 (TP53, 2 cases) and kirsten rat sarcoma (KRAS) viral proto-oncogene (1 case) were also detected. TERT promoter mutations are frequently present in PUC, which provides further evidence that TERT promoter mutations are common events in bladder cancer, regardless of histologic subtype, and supports their inclusion in any liquid biopsy assay for bladder cancer.
Collapse
Affiliation(s)
- Doreen N Palsgrove
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Pathology, Isfahan University of Medical Sciences, Isfahan Kidney Diseases Research Center, Isfahan 81746 73461, Iran
| | - Simeon U Springer
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
| | - Morgan Cowan
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
| | - Gunes Guner
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
| | | | - Maria Del Carmen Rodriguez Pena
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35249, USA
| | - Yuxuan Wang
- The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
| | - Isaac Kinde
- The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
| | | | - Isabela Cunha
- Department of Pathology, Rede D'OR São Luiz, São Paulo 03313-000, Brazil
| | | | - Dilek Ertoy
- Department of Pathology, Koç University, İstanbul 34450, Turkey
| | - Kenneth W Kinzler
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
| | | | - Nickolas Papadopoulos
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
| | - Bert Vogelstein
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
| | - George J Netto
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35249, USA.
| |
Collapse
|
21
|
Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, Ptak J, Dobbyn L, Papoli M, Kinde I, Afsari B, Tregnago AC, Bezerra SM, VandenBussche C, Fujita K, Ertoy D, Cunha IW, Yu L, Bivalacqua TJ, Grollman AP, Diaz LA, Karchin R, Danilova L, Huang CY, Shun CT, Turesky RJ, Yun BH, Rosenquist TA, Pu YS, Hruban RH, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Dickman KG, Netto GJ. Correction: Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife 2018; 7:43237. [PMID: 30418154 PMCID: PMC6231759 DOI: 10.7554/elife.43237] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
22
|
Daneshpajouhnejad P, Behzadi E, Amoushahi S, Aghabozorgi A, Farmani A, Hosseini SM, Taheri D. A six-year survey of the spectrum of renal disorders on native kidney biopsy results in Central Iran and a review of literature. Saudi J Kidney Dis Transpl 2018; 29:658-670. [PMID: 29970744 DOI: 10.4103/1319-2442.235191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Native kidney biopsy reports in previous studies that are mostly originated in Western countries show various results in different parts of the world. In this study, we aimed to determine the prevalence of renal biopsy disorders in Iran and compare it with that of other studies in the world. This cross-sectional study evaluated consecutive native kidney biopsies performed in four centers in Isfahan, Iran, from 2009 to 2014. We also reviewed other relevant studies in Iran and the world. Overall, 1547 renal biopsies were reviewed; 493 cases were excluded (transplant or re-biopsy cases) and 1054 cases (43.3% female) were included in our study with a mean (±standard deviation) age of 33.1 (±18.5) years. The first three most prevalent diagnoses were focal and segmental glomerulosclerosis (FSGS) (24.8%), minimal change disease (MCD) (14.2%), and membranous glomerulonephritis (MGN) (9.6%). IgA nephropathy (IgAN) was more prevalent among men, whereas lupus nephritis had a higher prevalence among women. In three out of six previous studies conducted in Iran, the most prevalent pathological diagnosis was MGN; in two others, MCD predominated; and in the third study, FSGS had the highest prevalence. In Europe and Western Pacific Region, IgAN was by far the most prevalent GN, while studies in other parts of the world show conflicting results. The most prevalent diagnosis in our study was FSGS, which was consistent with previous studies in Iran, which seems to have an increasing prevalence. It is recommended that having a national registry is crucial to determine the current status and for better planning and management of renal disorders.
Collapse
Affiliation(s)
- Parnaz Daneshpajouhnejad
- Student Research Committee, Isfahan Medical Students' Research Center, School of Medicine; Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Erfan Behzadi
- Student Research Committee, Isfahan Medical Students' Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Sanaz Amoushahi
- Student Research Committee, Isfahan Medical Students' Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Ahmadreza Aghabozorgi
- Student Research Committee, Isfahan Medical Students' Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Aida Farmani
- Student Research Committee, Isfahan Medical Students' Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Sayed-Mohsen Hosseini
- Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
23
|
Mazdak H, Ghavami M, Dolatkhah S, Daneshpajouhnejad P, Fesharakizadeh M, Fesharakizadeh S, Atapour A, Mahzouni P, Hashemi M, Salajegheh R, Taheri D. Pathological assessment of allograft nephrectomy: An Iranian experience. J Res Med Sci 2018; 23:55. [PMID: 30057639 PMCID: PMC6040153 DOI: 10.4103/jrms.jrms_440_17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Revised: 09/20/2017] [Accepted: 04/16/2018] [Indexed: 11/23/2022]
Abstract
BACKGROUND The aim of this study was to determine the pathologic causes of renal allograft failure in transplant nephrectomy specimens. MATERIALS AND METHODS In this cross-sectional study performed in the referral transplant center of Isfahan, Iran, medical files of all patients who underwent nephrectomy in 2008-2013 were studied. Age at transplantation, sex, donor's characteristics, causes of primary renal failure, duration of allograft function, and pathologic reasons of nephrectomy were extracted. Slides of nephrectomy biopsies were evaluated. Data were analyzed using SPSS. RESULTS Medical files of 39 individuals (male: 56.4%; mean age: 35.1 ± 16.0 years) were evaluated. The main disease of patients was hypertension (17.9%), and most cases (64.1%) were nephrectomized < 6 months posttransplantation. Renal vein thrombosis (RVT) (51.3%) and T-cell-mediated rejection (TCMR) (41.0%) were the most prevalent causes of transplanted nephrectomy. Cause of primary renal failure was correlated to nephrectomy result (P = 0.04). TCMR was the only pathologic finding in all of patients nephrectomized >2 years posttransplantation. There were 14 cases in which biopsy results showed a relationship between primary disease of patients and pathologic assessment of allograft (P = 0.04). A significant relationship between transplantation-nephrectomy interval and both the nephrectomy result and histopathologic result existed (P < 0.0001). A relationship between primary allograft biopsy appearance and further assessment of nephrectomized specimen (P < 0.001) existed as well. CONCLUSION The most pathologic diagnoses of nephrectomy in a period of less than and more than 6 months posttransplantation were RVT and TCMR, respectively. Early obtained allograft protocol biopsy is suggested, which leads to better diagnosis of allograft failure.
Collapse
Affiliation(s)
- Hamid Mazdak
- Department of Urology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mojgan Ghavami
- Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Shahaboddin Dolatkhah
- Department of Pathology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Parnaz Daneshpajouhnejad
- Isfahan Medical Students’ Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
- Department of Pathology, Isfahan Kidney Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mehdi Fesharakizadeh
- Department of Surgery, Najaf Abad Branch of Islamic Azad University, Isfahan, Iran
| | | | - Abdolamir Atapour
- Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Parvin Mahzouni
- Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mozaffar Hashemi
- Department of Thoracic Surgery, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Roxana Salajegheh
- Department of Pathology, Faculty of Medicine, Yazd University of Medical Sciences, Yazd, Iran
| | - Diana Taheri
- Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
24
|
Springer S, Rodriguez Pena MDC, Tregnago A, Taheri D, Bezerra S, Cunha I, Fujita K, Baydar D, Bivalacqua T, Papadopoulos N, Kinzler KW, Vogelstein B, Netto G. MP65-13 UROSEEK: A NOVEL NON-INVASIVE MOLECULAR METHOD FOR EARLY DETECTION OF BLADDER CANCER. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.2079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
25
|
Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. Am J Pathol 2018; 188:1478-1485. [PMID: 29577933 DOI: 10.1016/j.ajpath.2018.02.014] [Citation(s) in RCA: 109] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 02/19/2018] [Accepted: 02/22/2018] [Indexed: 12/22/2022]
Abstract
Antibodies targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-L1) interaction have shown clinical activity in multiple cancer types. PD-L1 protein expression is a clinically validated predictive biomarker of response for such therapies. Prior studies evaluating the expression of PD-L1 in primary prostate cancers have reported highly variable rates of PD-L1 positivity. In addition, limited data exist on PD-L1 expression in metastatic castrate-resistant prostate cancer (mCRPC). Here, we determined PD-L1 protein expression by immunohistochemistry using a validated PD-L1-specific antibody (SP263) in a large and representative cohort of primary prostate cancers and prostate cancer metastases. The study included 539 primary prostate cancers comprising 508 acinar adenocarcinomas, 24 prostatic duct adenocarcinomas, 7 small-cell carcinomas, and a total of 57 cases of mCRPC. PD-L1 positivity was low in primary acinar adenocarcinoma, with only 7.7% of cases showing detectable PD-L1 staining. Increased levels of PD-L1 expression were noted in 42.9% of small-cell carcinomas. In mCRPC, 31.6% of cases showed PD-L1-specific immunoreactivity. In conclusion, in this comprehensive evaluation of PD-L1 expression in prostate cancer, PD-L1 expression is rare in primary prostate cancers, but increased rates of PD-L1 positivity were observed in mCRPC. These results will be important for the future clinical development of programmed cell death protein 1/PD-L1-targeting therapies in prostate cancer.
Collapse
Affiliation(s)
- Michael C Haffner
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Gunes Guner
- Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Diana Taheri
- Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - George J Netto
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland; Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Doreen N Palsgrove
- Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Qizhi Zheng
- Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | | | - Kunhwa Kim
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Harrison Tsai
- Department of Pathology, Brigham and Women Hospital, Boston, Massachusetts
| | - David M Esopi
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Tamara L Lotan
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Rajni Sharma
- Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Alan K Meeker
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland; Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Arul M Chinnaiyan
- Michigan Center for Translational Pathology, University of Michigan Health System, Ann Arbor, Michigan; Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan
| | - William G Nelson
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland; Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Srinivasan Yegnasubramanian
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Jun Luo
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland; Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Rohit Mehra
- Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan
| | - Emmanuel S Antonarakis
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Charles G Drake
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland.
| | - Angelo M De Marzo
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland; Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland.
| |
Collapse
|
26
|
Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, Ptak J, Dobbyn L, Papoli M, Kinde I, Afsari B, Tregnago AC, Bezerra SM, VandenBussche C, Fujita K, Ertoy D, Cunha IW, Yu L, Bivalacqua TJ, Grollman AP, Diaz LA, Karchin R, Danilova L, Huang CY, Shun CT, Turesky RJ, Yun BH, Rosenquist TA, Pu YS, Hruban RH, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Dickman KG, Netto GJ. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife 2018; 7:32143. [PMID: 29557778 PMCID: PMC5860864 DOI: 10.7554/elife.32143] [Citation(s) in RCA: 97] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 02/19/2018] [Indexed: 12/15/2022] Open
Abstract
Current non-invasive approaches for detection of urothelial cancers are suboptimal. We developed a test to detect urothelial neoplasms using DNA recovered from cells shed into urine. UroSEEK incorporates massive parallel sequencing assays for mutations in 11 genes and copy number changes on 39 chromosome arms. In 570 patients at risk for bladder cancer (BC), UroSEEK was positive in 83% of those who developed BC. Combined with cytology, UroSEEK detected 95% of patients who developed BC. Of 56 patients with upper tract urothelial cancer, 75% tested positive by UroSEEK, including 79% of those with non-invasive tumors. UroSEEK detected genetic abnormalities in 68% of urines obtained from BC patients under surveillance who demonstrated clinical evidence of recurrence. The advantages of UroSEEK over cytology were evident in low-grade BCs; UroSEEK detected 67% of cases whereas cytology detected none. These results establish the foundation for a new non-invasive approach for detection of urothelial cancer.
Collapse
Affiliation(s)
- Simeon U Springer
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Chung-Hsin Chen
- Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
| | - Maria Del Carmen Rodriguez Pena
- Department of Pathology, Johns Hopkins University, Baltimore, United States.,Department of Pathology, University of Alabama at Birmingham, Birmingham, United States
| | - Lu Li
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States
| | - Christopher Douville
- Department of Biomedical Engineering, Institute for Computational Medicine, Johns Hopkins University, Baltimore, United States
| | - Yuxuan Wang
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Joshua David Cohen
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, Baltimore, United States.,Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Natalie Silliman
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Joy Schaefer
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Janine Ptak
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Lisa Dobbyn
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Maria Papoli
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Isaac Kinde
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Bahman Afsari
- Department of Oncology, Johns Hopkins University, Baltimore, United States.,Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, United States
| | - Aline C Tregnago
- Department of Pathology, Johns Hopkins University, Baltimore, United States
| | | | | | | | - Dilek Ertoy
- Department of Pathology, Hacettepe University, Ankara, Turkey
| | - Isabela W Cunha
- Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil
| | - Lijia Yu
- Department of Pathology, University of Alabama at Birmingham, Birmingham, United States
| | | | - Arthur P Grollman
- Department of Pharmacological Sciences, Stony Brook University, Stony Brook, United States.,Department of Medicine, Stony Brook University, Stony Brook, United States
| | - Luis A Diaz
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
| | - Rachel Karchin
- Department of Biomedical Engineering, Institute for Computational Medicine, Johns Hopkins University, Baltimore, United States.,Department of Oncology, Johns Hopkins University, Baltimore, United States
| | - Ludmila Danilova
- Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, United States.,Department of Pathology, Hacettepe University, Ankara, Turkey
| | - Chao-Yuan Huang
- Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
| | - Chia-Tung Shun
- Department of Forensic Medicine and Pathology, National Taiwan University Hospital, Taipei, Taiwan
| | - Robert J Turesky
- Masonic Cancer Center, University of Minnesota, Minneapolis, United States.,Department of Medicinal Chemistry, University of Minnesota, Minneapolis, United States
| | - Byeong Hwa Yun
- Masonic Cancer Center, University of Minnesota, Minneapolis, United States.,Department of Medicinal Chemistry, University of Minnesota, Minneapolis, United States
| | - Thomas A Rosenquist
- Department of Pharmacological Sciences, Stony Brook University, Stony Brook, United States
| | - Yeong-Shiau Pu
- Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
| | - Ralph H Hruban
- Department of Pathology, Johns Hopkins University, Baltimore, United States
| | - Cristian Tomasetti
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States.,Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, United States
| | - Nickolas Papadopoulos
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Ken W Kinzler
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Bert Vogelstein
- Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, United States.,Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States
| | - Kathleen G Dickman
- Department of Pharmacological Sciences, Stony Brook University, Stony Brook, United States.,Department of Medicine, Stony Brook University, Stony Brook, United States
| | - George J Netto
- Department of Pathology, Johns Hopkins University, Baltimore, United States.,Department of Pathology, University of Alabama at Birmingham, Birmingham, United States
| |
Collapse
|
27
|
Rodriguez Pena MDC, Tregnago AC, Eich ML, Springer S, Wang Y, Taheri D, Ertoy D, Fujita K, Bezerra SM, Cunha IW, Raspollini MR, Yu L, Bivalacqua TJ, Papadopoulos N, Kinzler KW, Vogelstein B, Netto GJ. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Arch 2017; 471:761-767. [PMID: 28597078 DOI: 10.1007/s00428-017-2164-5] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 05/19/2017] [Accepted: 05/26/2017] [Indexed: 12/26/2022]
Abstract
Our group and others have previously demonstrated the presence of TERT promoter mutations (TERT-mut) in 60-80% of urothelial carcinomas and some of their histologic variants. Five other genes have been frequently implicated in bladder cancer: FGRF3, TP53, PIK3CA, HRAS, and CDKN2A. In the current study, we sought to determine the prevalence of mutations in TERT and these five other genes in de novo papillary urothelial neoplasms of low malignant potential (PUNLMP) of the urinary bladder. A retrospective search of our archives for PUNLMP was performed and 30 de novo cases were identified and included in the study. We found mutations in TERT (TERT-mut) and FGFR3 (FGFR3-mut) to be the most common alterations in the cohort (63 and 60%, respectively). The majority of the TERT-mut-positive tumors (84%) had a g.1295228C > T alteration with the remaining tumors demonstrating g.1295250C > T. Approximately one fourth of tumors had TP53 mutations. These findings support the potential utility of a uniform genetic mutation panel to detect bladder cancers of various subtypes.
Collapse
Affiliation(s)
| | - Aline C Tregnago
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA
| | - Marie-Lisa Eich
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA
| | - Simeon Springer
- The Ludwig Center and Howard Hughes Medical Institute at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Yuxuan Wang
- The Ludwig Center and Howard Hughes Medical Institute at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA
| | - Dilek Ertoy
- Department of Pathology, Hacettepe University, Ankara, Turkey
| | | | | | - Isabela W Cunha
- Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil
| | | | - Lijia Yu
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35249, USA
| | | | - Nickolas Papadopoulos
- The Ludwig Center and Howard Hughes Medical Institute at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Kenneth W Kinzler
- The Ludwig Center and Howard Hughes Medical Institute at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Bert Vogelstein
- The Ludwig Center and Howard Hughes Medical Institute at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - George J Netto
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA.
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35249, USA.
- Department of Pathology, The University of Alabama at Birmingham, WP Building, Suite P230, 619 19th Street South, Birmingham, AL, 35249-7331, USA.
| |
Collapse
|
28
|
Rodriguez Pena MDC, Tregnago AC, Chaux A, Taheri D, Borhan W, Rezaei K, Eich ML, Nonogaki H, Sharma R, Netto GJ. MP44-06 IMMUNOHISTOCHEMICAL EVALUATION OF BASAL AND LUMINAL MARKERS IN NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF BLADDER (NMIBC). J Urol 2017. [DOI: 10.1016/j.juro.2017.02.1337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Tregnago AC, Rodriguez Pena MDC, Eich ML, Taheri D, Nonogaki H, Sharma R, McConkey D, Bivalacqua TJ, Netto GJ, Baras A. MP58-05 BASAL AND LUMINAL IMMUNOHISTOCHEMICAL PHENOTYPES IN MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMAS (MIBC) TREATED WITH NEOADJUVANT CHEMOTHERAPY (NAC). J Urol 2017. [DOI: 10.1016/j.juro.2017.02.1800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
30
|
Cocks M, Taheri D, Ball MW, Bezerra SM, Del Carmen Rodriguez M, Ricardo BF, Bivalacqua TJ, Sharma RB, Meeker A, Chaux A, Burnett AL, Netto GJ. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol 2017; 59:55-61. [DOI: 10.1016/j.humpath.2016.09.003] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Revised: 08/29/2016] [Accepted: 09/01/2016] [Indexed: 10/21/2022]
|
31
|
Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Ricardo BFP, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch 2016; 469:427-34. [PMID: 27520411 DOI: 10.1007/s00428-016-2001-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 07/16/2016] [Accepted: 08/02/2016] [Indexed: 12/22/2022]
Abstract
Somatic activating mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the most common genetic alterations in urothelial carcinoma (UC) of the bladder and upper urinary tract. Little is known, however, about TERT-mutation status in the relatively uncommon but clinically aggressive micropapillary (MPC) variant. We evaluated the presence of TERT promoter mutations in MPC of the bladder and upper urinary tract. A retrospective search of our archives for MPC and UC with micropapillary features (2005-2014) was performed. All slides were reviewed to confirm the histologic diagnosis. Thirty-three specimens from 31 patients had FFPE blocks available for DNA analysis and were included in the study. Intratumoral areas of non-micropapillary histology were also evaluated when present. Samples were analyzed with Safe-SeqS, a sequencing error reduction technology, and sequenced using the Illumina MiSeq platform. TERT promoter mutations were detected in all specimens with pure MPC (18 of 18) and UC with focal micropapillary features (15 of 15). Similar to conventional UC, the predominant mutations identified occurred at positions -124 (C228T) (85 %) and -146 (C250T) (12 %) bp upstream of the TERT ATG start site. In heterogeneous tumors with focal variant histology, intratumoral concordant mutations were found in variant (MPC and non-MPC) and corresponding conventional UC. We found TERT promoter mutations, commonly found in conventional UC, to be frequently present in MPC. Our finding of concordant intratumoral mutational alterations in cases with focal variant histology lends support to the common oncogenesis origin of UC and its variant histology.
Collapse
Affiliation(s)
- Doreen Nguyen
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA.,Department of Pathology, Isfahan University of Medical Sciences, Isfahan Kidney Diseases Research Center, Isfahan, Iran
| | - Simeon Springer
- Department of Oncology, Johns Hopkins University, Baltimore, MD, 21287, USA.,The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Morgan Cowan
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA
| | - Gunes Guner
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA
| | | | - Yuxuan Wang
- The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Isaac Kinde
- The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | | | - Matthew T Olson
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA
| | | | | | | | - Dilek Ertoy
- Department of Pathology, Hacettepe University, Ankara, Turkey
| | - Kenneth W Kinzler
- Department of Oncology, Johns Hopkins University, Baltimore, MD, 21287, USA.,The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | | | - Nickolas Papadopoulos
- Department of Oncology, Johns Hopkins University, Baltimore, MD, 21287, USA.,The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Bert Vogelstein
- Department of Oncology, Johns Hopkins University, Baltimore, MD, 21287, USA.,The Ludwig Center for Cancer Genetics and Therapeutics and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - George J Netto
- Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA. .,Department of Urology, Johns Hopkins University, Baltimore, MD, 21287, USA. .,Department of Pathology, The Johns Hopkins Hospital, 401 North Broadway Street, Weinberg 2242, Baltimore, MD, 21231, USA.
| |
Collapse
|
32
|
Guner G, Bishop JA, Bezerra SM, Taheri D, Zahavi DJ, Mendoza Rodriguez MA, Sharma R, Epstein JI, Netto GJ. The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. Hum Pathol 2016; 54:184-8. [DOI: 10.1016/j.humpath.2016.03.011] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Revised: 03/11/2016] [Accepted: 03/24/2016] [Indexed: 01/16/2023]
|
33
|
Atapour A, Nasr S, Boroujeni AM, Taheri D, Dolatkhah S. A comparison of the quality of life of the patients undergoing hemodialysis versus peritoneal dialysis and its correlation to the quality of dialysis. Saudi J Kidney Dis Transpl 2016; 27:270-80. [PMID: 26997380 DOI: 10.4103/1319-2442.178259] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Over the years, there has been a steady increase in the number of patients requiring dialysis. However, no consensus exists between choosing either hemodialysis (HD) or peritoneal dialysis (PD) as the preferred method of dialysis for patients. In this study, we have compared the quality of life of the patients undergoing either HD or PD. This cross-sectional study was performed in the dialysis center of the Noor and Saint Ali Asghar University Hospital in Isfahan, Iran in 2012. Forty-six patients who underwent PD (28 males and 18 females) and 46 similar patients undergoing HD (26 males and 20 females) were compared. A standardized Persian version of the short form-36 (SF-36) tool was used to assess the quality of life and to assess the quality of dialysis weekly Kt/V in patients undergoing PD and single random Kt/V sampling in HD patients were assessed. Patients undergoing PD reported higher scores in physical functioning. The lowest scores in both groups were reported in mental health section. In physical functioning section, physical role functioning section and overall score of the SF-36 tool, PD patients reported significantly higher scores compared to the HD patients (P <0.05). There was no significant difference between the qualities of the dialysis in the two patient groups. Aspects of quality of life such as physical functioning, physical role functioning, bodily pain, general health perceptions, and overall score were significantly different between the two groups. If these results are substantiated by subsequent longitudinal studies, then the choice of dialysis could be better guided in patients by the quality of life issues.
Collapse
Affiliation(s)
- Abdolamir Atapour
- Department of Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | | | | | | |
Collapse
|
34
|
Shekhani MT, Barber JR, Bezerra SM, Heaphy CM, Gonzalez Roibon ND, Taheri D, Reis LO, Guner G, Joshu CE, Netto GJ, Meeker AK. High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors. Hum Pathol 2016; 54:106-12. [PMID: 27085557 DOI: 10.1016/j.humpath.2016.03.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Revised: 03/23/2016] [Accepted: 03/31/2016] [Indexed: 12/26/2022]
Abstract
Testicular germ cell tumor (TGCT) is the most common malignancy of young men. Most patients are completely cured, which distinguishes these from most other malignancies. Orchiectomy specimens (n=76) were evaluated using high-resolution (single-cell discriminative) telomere-specific fluorescence in situ hybridization (FISH) with simultaneous Oct4 immunofluorescence to describe telomere length phenotype in TGCT neoplastic cells. For the first time, the TGCT precursor lesion, germ cell neoplasia in situ (GCNIS) is also evaluated in depth. The intensity of the signals from cancerous cells was compared to the same patient's reference cells-namely, healthy germ cells (defined as "medium" length) and interstitial/somatic cells (defined as "short" telomere length). We observed short telomeres in most GCNIS and pure seminomas (P=.006 and P=.0005, respectively). In contrast, nonseminomas displayed longer telomeres. Lesion-specific telomere lengths were documented in mixed tumor cases. Embryonal carcinoma (EC) demonstrated the longest telomeres. A fraction of EC displays the telomerase-independent alternative lengthening of telomeres (ALT) phenotype (24% of cases). Loss of ATRX or DAXX nuclear expression was strongly associated with ALT; however, nuclear expression of both proteins was retained in half of ALT-positive ECs. The particular distribution of telomere lengths among TGCT and GCNIS precursors implicate telomeres anomalies in pathogenesis. These results may advise management decisions as well.
Collapse
Affiliation(s)
- Mohammed Talha Shekhani
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - John R Barber
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
| | - Stephania M Bezerra
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Christopher M Heaphy
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
| | | | - Diana Taheri
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Leonardo O Reis
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Gunes Guner
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Corinne E Joshu
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
| | - George J Netto
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, James Buchanan Brady Urological Institute at Johns Hopkins, Baltimore, MD
| | - Alan K Meeker
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, James Buchanan Brady Urological Institute at Johns Hopkins, Baltimore, MD.
| |
Collapse
|
35
|
Cocks M, Taheri D, Ball MW, Bezerra SM, Meeker A, Del Carmen Rodriguez M, Chaux A, Burnett A, Netto G. MP81-19 PROGRAMMED DEATH LIGAND-1 (PD-L1) STATUS IN NORTH AMERICAN COHORT OF PENILE SQUAMOUS CELL CARCINOMA. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Cowan ML, Springer S, Nguyen D, Taheri D, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, Del Carmen Rodriguez Pena M, VandenBussche CJ, Olson MT, Cunha I, Fujita K, Ertoy D, Kinzler K, Bivalacqua T, Papadopoulos N, Vogelstein B, Netto GJ. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Hum Pathol 2016; 53:8-13. [PMID: 26980028 DOI: 10.1016/j.humpath.2016.02.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Revised: 02/09/2016] [Accepted: 02/12/2016] [Indexed: 12/13/2022]
Abstract
TERT promoter mutations (TERT-mut) have been detected in 60% to 80% of urothelial carcinomas. A molecular urine-based screening assay for the detection of TERT-mut is currently being pursued by our group and others. A small but significant number of bladder carcinomas are adenocarcinoma. The current study assesses the incidence of TERT-mut in primary adenocarcinomas of urinary bladder. A retrospective search of our institutional pathology records identified 23 cystectomy specimens with a diagnosis of adenocarcinoma (2000-2014). All slides were reviewed by a senior urologic pathologist to confirm tumor type and select a representative formalin-fixed, paraffin-embedded block for mutational analysis. Adequate material for DNA testing was available in 14 cases (7 enteric type and 7 not otherwise specified). TERT-mut sequencing analysis was performed using previously described SafeSeq technique. Overall, 28.5% of primary adenocarcinoma harbored TERT-mut. Interestingly, 57% of nonenteric adenocarcinomas were mutation positive, whereas none of the enteric-type tumors harbored mutations. Similar to urothelial carcinoma, we found a relatively higher rate of TERT-mut among nonenteric-type adenocarcinomas further supporting the potential utility of TERT-mut urine-based screening assay for bladder cancer.
Collapse
Affiliation(s)
- Morgan L Cowan
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287
| | - Simeon Springer
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21287; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231
| | - Doreen Nguyen
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287
| | - Gunes Guner
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287
| | | | - Yuxuan Wang
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231
| | - Isaac Kinde
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231
| | | | | | - Mathew T Olson
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287
| | - Isabela Cunha
- AC Camargo Cancer Centre, Sao Paulo, Brazil, 01509-010
| | | | - Dilek Ertoy
- Department of Pathology, Hacettepe University, Ankara, Turkey 06100
| | - Kenneth Kinzler
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21287; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231
| | | | - Nickolas Papadopoulos
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21287; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231
| | - Bert Vogelstein
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21287; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231
| | - George J Netto
- Department of Pathology, Johns Hopkins University, Baltimore, MD 21287; Department of Urology, Johns Hopkins University, Baltimore, MD 21287.
| |
Collapse
|
37
|
Munari E, Chaux A, Vaghasia AM, Taheri D, Karram S, Bezerra SM, Gonzalez Roibon N, Nelson WG, Yegnasubramanian S, Netto GJ, Haffner MC. Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. PLoS One 2016; 11:e0146302. [PMID: 26785262 PMCID: PMC4718593 DOI: 10.1371/journal.pone.0146302] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 12/15/2015] [Indexed: 01/22/2023] Open
Abstract
Solid tumors are characterized by a plethora of epigenetic changes. In particular, patterns methylation of cytosines at the 5-position (5mC) in the context of CpGs are frequently altered in tumors. Recent evidence suggests that 5mC can get converted to 5-hydroxylmethylcytosine (5hmC) in an enzymatic process involving ten eleven translocation (TET) protein family members, and this process appears to be important in facilitating plasticity of cytosine methylation. Here we evaluated the global levels of 5hmC using a validated immunohistochemical staining method in a large series of clear cell renal cell carcinoma (n = 111), urothelial cell carcinoma (n = 55) and testicular germ cell tumors (n = 84) and matched adjacent benign tissues. Whereas tumor-adjacent benign tissues were mostly characterized by high levels of 5hmC, renal cell carcinoma and urothelial cell carcinoma showed dramatically reduced staining for 5hmC. 5hmC levels were low in both primary tumors and metastases of clear cell renal cell carcinoma and showed no association with disease outcomes. In normal testis, robust 5hmC staining was only observed in stroma and Sertoli cells. Seminoma showed greatly reduced 5hmC immunolabeling, whereas differentiated teratoma, embryonal and yolk sack tumors exhibited high 5hmC levels. The substantial tumor specific loss of 5hmC, particularly in clear cell renal cell carcinoma and urothelial cell carcinoma, suggests that alterations in pathways involved in establishing and maintaining 5hmC levels might be very common in cancer and could potentially be exploited for diagnosis and treatment.
Collapse
Affiliation(s)
- Enrico Munari
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
| | - Alcides Chaux
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- Department of Scientific Research, Norte University; Centro para el Desarrollo de la Investigación Científica (CEDIC) Asunción, Asunción, Paraguay
| | - Ajay M. Vaghasia
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
| | - Diana Taheri
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- Department of Pathology, Isfahan University of Medical Sciences, Isfahan Kidney Diseases Research Center, Isfahan, Iran
| | - Sarah Karram
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
| | - Stephania M. Bezerra
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
| | - Nilda Gonzalez Roibon
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
| | - William G. Nelson
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
| | - Srinivasan Yegnasubramanian
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
| | - George J. Netto
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- * E-mail: (MCH); (GJN)
| | - Michael C. Haffner
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, 21231, United States of America
- * E-mail: (MCH); (GJN)
| |
Collapse
|
38
|
Abstract
There is an increasing need for renal replacement therapy due to the growing number of cases with chronic kidney disease leading to end-stage renal disease. Two modalities of dialysis available are hemodialysis (HD) and peritoneal dialysis (PD). In this study, we aimed to compare the financial aspects of HD with PD. A total of 53 patients on HD and 43 patients on PD were included in the study and were assessed for several financial aspects of dialysis. The data collected were analyzed using SPSS-18. A statistically significant difference was noted between the HD and PD groups in the need for diagnostic tests, drugs, hospitalization, etc, with PD being less expensive. We strongly suggest physicians in our area to use PD on a larger number of patients for better financial outcome.
Collapse
Affiliation(s)
- Abdolamir Atapour
- Department of Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | | | | |
Collapse
|
39
|
Taheri D, Gheissari A, Shaabani P, Tabibian SR, Mortazavi M, Seirafian S, Merrikhi A, Fesharakizadeh M, Dolatkhah S. Acute oxalate nephropathy following kidney transplantation: Report of three cases. J Res Med Sci 2015; 20:818-23. [PMID: 26664431 PMCID: PMC4652317 DOI: 10.4103/1735-1995.168408] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Calcium oxalate (CaOx) crystal deposition is a common finding immediately after kidney transplantation. However, small depositions of CaOx could be benign while extensive depositions lead to poor graft outcome. Here we report three cases with end-stage renal disease (ESRD), bilateral nephrolithiasis, and unknown diagnosis of primary hyperoxaluria (PH) who underwent a renal transplant and experienced an early-onset graft failure. Although an acute rejection was suspected, renal allograft biopsies and subsequent allograft nephrectomies showed extensive CaOx deposition, which raised a suspicion of PH. Even though increased urinary excretion of CaOx was found in all patients, this diagnosis could be confirmed with further tests including genetic study and metabolic assay. In conclusion, massive CaOx deposition in kidney allograft is an important cause of poor allograft survival and needs special management. Furthermore, our cases suggest patients with ESRD and a history of nephrolithiasis should be screened for elevated urinary oxalate excretion and rule out of PH.
Collapse
Affiliation(s)
- Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran ; Department of Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Alaleh Gheissari
- Department of Pediatric Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Pooria Shaabani
- Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | - Mojgan Mortazavi
- Department of Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Shiva Seirafian
- Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Alireza Merrikhi
- Department of Pediatric Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mehdi Fesharakizadeh
- Department of Surgery, School of Medicine, Islamic Azad University, Najaf Abad Branch, Isfahan, Iran
| | | |
Collapse
|
40
|
Ozluk Y, Taheri D, Matoso A, Sanli O, Berker NK, Yakirevich E, Balasubramanian S, Ross JS, Ali SM, Netto GJ. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. Hum Pathol 2015; 46:1951-5. [DOI: 10.1016/j.humpath.2015.07.027] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 07/28/2015] [Indexed: 02/09/2023]
|
41
|
Taheri D, Sarmadi T, Shahidi S, Taheri S, Mortazavi M, Atapour A, Dolatkhah S, Moayednia R. Oxalate nephropathy after Jejuno-Ileal bypass surgery. Saudi J Kidney Dis Transpl 2015; 26:1026-7. [PMID: 26354586 DOI: 10.4103/1319-2442.164599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Mortazavi N, Mahzooni P, Taheri D, Jalilian M, Novin K. Germ Cell Tumor's Survival Rate in Young Patients. Iran J Cancer Prev 2015; 8:e3440. [PMID: 26478797 PMCID: PMC4606379 DOI: 10.17795/ijcp.3440] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 07/11/2015] [Indexed: 12/16/2022]
Abstract
BACKGROUND Germ cell tumors are neoplasms that originate from multi potential germ cells and can be intra or extra gonadal. According to pathologic classification, they have different subtypes. They account for 3% of pediatric malignancies and most commonly happen in children before the age of 15 years old. Epidemiologic evidence about pediatric germ cell tumors is scant in our region. OBJECTIVES The aim of current study was to determine demographic characteristics, recurrence and survival rate of germ cell tumor patients under the age of 21 years. PATIENTS AND METHODS During a 10-year period (1996 - 2006), 106 patients under the age of 21 years suffering from germ cell tumor were admitted to our centers. We extracted the data needed for our study from patients' medical records in the hospitals. RESULTS Thirty seven boys and 69 girls with a mean age of 8.4 ± 7.8 years were included. Most tumors were diagnosed before the age of one year (37%). The most common pathologic subtype was mature teratoma (44%). Ovary (35%) was the most common primary site. Surgery plus chemotherapy were used to treat 54 patients and BEP was the most common chemotherapy regimen. Metastasis and recurrent tumor were seen in 22% and 8% of cases, respectively. Four-year overall survival was 89%. CONCLUSIONS Our study showed that demographic characteristics of GCT patients in our population are similar to patients of other geographic regions in the world. Primary tumor site, histologic subtype and metastasis were significant prognostic factors for survival.
Collapse
Affiliation(s)
- Nafiseh Mortazavi
- Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| | - Parvin Mahzooni
- Department of Pathology, Isfahan University of Medical Sciences, Isfahan, IR Iran
| | - Diana Taheri
- Department of Pathology, Isfahan University of Medical Sciences, Isfahan, IR Iran
| | - Mahshid Jalilian
- Department of Radiation Oncology, Isfahan University of Medical Sciences, Isfahan, IR Iran
| | - Kambiz Novin
- Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| |
Collapse
|
43
|
Afshar Moghaddam N, Mahsuni P, Taheri D. Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma. Iran J Pathol 2015; 10:89-96. [PMID: 26351468 PMCID: PMC4539765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Accepted: 03/18/2014] [Indexed: 06/05/2023]
Abstract
BACKGROUND AND OBJECTIVES Angiogenesis is essential for growth and metastasis of solid malignancies. Tumor vessel count and expression of vascular endothelial growth factor (VEGF), a potent angiogenic factor, have been associated with prognosis. This study was designed to assess vessels density by using CD31 and CD105 (Endoglin) and their correlation with expression of VEGF and proliferative index (Ki67) in Glioblastoma multiforme (GBM). METHODS We examined these parameters in GBM specimens from 50 adult patients; referred to Al-Zahra hospital Pathology Lab between 2001 to 2006.These patients did not receive pre-operative therapy. Paraffin-embedded tumor specimens were immunohistochemically stained for CD31, CD105 (Endoglin), VEGF and Ki67 (proliferation index) monoclonal antibodies. Microvessel density (MVD) was evaluated by immunostaining for CD31 and CD105.Then the results were compared between the two and also with VEGF receptors and Ki67 index. RESULTS CD105-MVD was significantly higher in Glioblastoma compared with peritumoral normal (14.28 vs. 6.68: P=0.012). We did not find such difference for CD31. The mean of CD105-MVD was significantly higher than CD31-MVD in Glioblastoma tissue (P<0.001) although there was a significant positive relationship between them (Pearson's r=0.630 P<0.001).The VEGF scoring for tumoral tissue was 12 % (score:1), 46% (score:2) and 42% (score:3).For peritumoral normal tissue were 92% (score:1) and 8% (score:2) . So they reach to statistical significance (Chi Square, P = 0001). Both MVD of CD105 and CD31 have significant relationship with VEGF (P<0.001). CONCLUSION We suggest that Endoglin can be used as a specific and sensitive marker for evaluation of angiogenesis in Glioblastoma.
Collapse
Affiliation(s)
| | - Parvin Mahsuni
- Dept. of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Diana Taheri
- Dept. of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
44
|
Taheri D, Soleimani N, Fesharakizadeh M, Dolatkhah S, Kabiri M, Gholipour A. Inflammatory myofibroblastic tumor: report of a rare case in kidney. Iran J Kidney Dis 2014; 8:333-335. [PMID: 25001141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/04/2013] [Revised: 06/24/2013] [Accepted: 12/29/2013] [Indexed: 06/03/2023]
Abstract
Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm mostly seen in the lungs, but also in extrapulmonary sites. The most common genitourinary site of IMT is the bladder, but it may rarely be seen in the kidneys. We report a case of a 15-year-old girl presented with flank pain and hematuria, in which computed tomography scan revealed a mass in the left kidney. The patient underwent left nephrectomy for a diagnosis of Wilms tumor. Further assessment of the tissue demonstrated a pathologic diagnosis of IMT. Despite improvements in imaging technology, the preoperative diagnosis of IMT remains difficult and surgery is the only way for the diagnosis and treatment. Considering the role of the pathologic examination in making the definite diagnosis of IMT, we should be aware of this entity and it must be considered in the differential diagnoses.
Collapse
Affiliation(s)
- Diana Taheri
- Department of Pathology, Isfahan University of Medical Sciences; Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences; Isfahan, Iran.
| | | | | | | | | | | |
Collapse
|
45
|
Mortazavi M, Seyrafian S, Moein N, Taheri D, Dolatkhah S. Metabolic syndrome in end stage renal disease. J Res Med Sci 2014; 19:685. [PMID: 25364373 PMCID: PMC4214032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Mojgan Mortazavi
- Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Shiva Seyrafian
- Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Nafiseh Moein
- Medical Student, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Diana Taheri
- Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Shahaboddin Dolatkhah
- Medical Student, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran,Address for correspondence: Dr. Shahaboddin Dolatkhah, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail:
| |
Collapse
|
46
|
Roomizadeh P, Taheri D, Abedini A, Mortazavi M, Larry M, Mehdikhani B, Mousavi SM, Hosseini FA, Parnia A, Nakhjavani M. Limited knowledge of chronic kidney disease and its main risk factors among Iranian community: an appeal for promoting national public health education programs. Int J Health Policy Manag 2014; 2:161-6. [PMID: 24847481 DOI: 10.15171/ijhpm.2014.37] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2014] [Accepted: 04/20/2014] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND The aim of this survey was to explore the baseline knowledge of the Iranian community about Chronic Kidney Disease (CKD) definition and its two main risk factors, i.e. diabetes and hypertension. This study also introduced a model of public education program with the purpose of reducing the incidence of CKD in high-risk groups and thereby decreasing the economic burden of CKD in Iran. METHODS This cross-sectional study was conducted on world kidney day 2013 in Isfahan, Iran. Self-administered anonymous questionnaires evaluating the knowledge of CKD and its risk factors were distributed among subjects who participated in a kidney disease awareness campaign. Chi-square test and logistic regression analysis were used to examine the differences in the level of knowledge across different socio-demographic groups. RESULTS The questionnaires were completed by 748 respondents. The majority of these respondents believed that "pain in the flanks" and "difficulty in urination" was the early symptoms of CKD. Roughly, 10.4% knew that CKD could be asymptomatic in the initial stages. Only 12.7% knew diabetes and 14.4% knew hypertension was a CKD risk factor. The respondents who had a CKD risk factor (i.e. diabetes and/or hypertension) were significantly more likely than respondents without CKD risk factor to select "unmanaged diabetes" [Odds Ratio (OR)= 2.2, Confidence Interval (CI) (95%): 1.4-3.6] and "unmanaged hypertension" [OR= 1.9, CI(95%): 1.2-3.0] as "very likely to result in CKD". No more than 34.6% of all respondents with diabetes and/or hypertension reported that their physician has ever spoken with them about their increased risk for developing CKD. CONCLUSION The knowledge of Iranian population about CKD and its risk factors is low. Future public health education programs should put efforts in educating Iranian community about the asymptomatic nature of CKD in its initial stages and highlighting the importance of regular renal care counseling. The high-risk individuals should receive tailored education and be encouraged to adopt lifestyle modifications to prevent or slow the progression of CKD.
Collapse
Affiliation(s)
- Peyman Roomizadeh
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ; Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Diana Taheri
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ; Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Amin Abedini
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ; Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mojgan Mortazavi
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ; Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mehrdad Larry
- Endocrinology and Diabetes Division, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Bahareh Mehdikhani
- Endocrinology and Diabetes Division, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Seyed-Mojtaba Mousavi
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ; Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Farid-Aldin Hosseini
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ; Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Aidin Parnia
- Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ; Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Manouchehr Nakhjavani
- Endocrinology and Diabetes Division, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
47
|
Minaiyan M, Zolfaghari B, Taheri D, Gomarian M. Preventive Effect of Three Pomegranate (Punica granatum L.) Seeds Fractions on Cerulein-Induced Acute Pancreatitis in Mice. Int J Prev Med 2014; 5:394-404. [PMID: 24829726 PMCID: PMC4018587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Accepted: 11/26/2013] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Acute pancreatitis (AP) refers to afflicted inflammation of pancreas with unfavorable adverse effects and developed multiple organ failures. Unfortunately, there is not a certain therapeutic method for this disease. Oxidative stress has a serious role in the pathogenesis of AP. Thus, decreasing of oxidative stress may prevent induction and progression of AP. Punica granatum L. has been extensively used in traditional medicine and possesses various active biological elements. Due to antioxidant and anti-inflammatory properties of pomegranate, it could be considered as a good candidate alternative medicine with beneficial effects on AP. In this study, we decided to study the protective effect of three fractions of pomegranate seeds on cerulein-induced AP. METHODS AP was induced in male Syrian mice by five intraperitoneal (i.p.) injection of cerulein (50 μg/kg) with 1 h intervals. Treatments with pomegranate freeze-dried powder (PFDP) and hydroalcoholic pomegranate seeds extract (PSE) at doses of 125, 250, 500 mg/kg (i.p.) were started 30 min before pancreatitis induction. Pomegranate seed oil fraction (PSOF) was orally administered (50, 100, 200 μL/kg) and continued for 10 days. Pancreatic tissue was evaluated for histopathological parameters and pancreatic myeloperoxidase (MPO) activity as well as lipase and amylase levels were measured in plasma. RESULTS The higher doses of three fractions (250 and 500 mg/kg for PFDP and PSE and doses of 100, 200 μL/kg for PSOF) significantly reduced amylase and lipase activity in serum (at least P < 0.01), pancreatic MPO activity (P < 0.001), edema, leukocyte infiltration and vacuolization in comparison to the control group (P < 0.05). CONCLUSIONS These results propose that pomegranate seeds fractions can prevent and/or treat the AP.
Collapse
Affiliation(s)
- Mohsen Minaiyan
- Department of Pharmacology, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran,Correspondence to: Prof. Mohsen Minaiyan, Department of Pharmacology, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail:
| | - Behzd Zolfaghari
- Department of Pharmacognosy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Diana Taheri
- Department of Clinical Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mahdi Gomarian
- School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
48
|
Talaei A, Aminorroaya A, Taheri D, Mahdavi KN. Carney complex presenting with a unilateral adrenocortical nodule: a case report. J Med Case Rep 2014; 8:38. [PMID: 24499519 PMCID: PMC3927851 DOI: 10.1186/1752-1947-8-38] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Accepted: 12/16/2013] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Carney complex is an autosomal dominant syndrome with multiple neoplasms in different sites, including myxomas, endocrine tumors and lentigines lesions. To the best of our knowledge, this is the first report of Carney complex presenting with a unilateral adrenal adenoma associated with a pituitary incidentaloma. CASE PRESENTATION A 27-year-old Iranian woman was referred to our endocrinology clinic with amenorrhea and hirsutism, further confirming a diagnosis of adrenocorticotropic hormone-independent Cushing's syndrome. The cause was believed to be a right adrenocortical adenoma based on a computed tomography scan. Our patient underwent a right laparoscopic adrenalectomy and pathological examination revealed pigmented micronodular adrenal hyperplasia. Pituitary magnetic resonance imaging also documented a microadenoma that was considered to be an incidentaloma based on normal pituitary function tests. Recurrence of hypercortisolism led to a left laparoscopic adrenalectomy, providing further evidence for the diagnosis of primary pigmented nodular adrenocortical disease. Carney complex was established in light of her history of cardiac myxomas. CONCLUSION We present what we believe to be the first case of Carney complex presenting with a unilateral adrenocortical adenoma in association with a pituitary incidentaloma. Although primary pigmented nodular adrenocortical disease is rare as a component of Carney complex, it should be considered in the differential diagnosis of Cushing's syndrome. Rarely, adrenal and pituitary imaging can be misleading.
Collapse
Affiliation(s)
- Afsaneh Talaei
- Thyroid Disorders Research Center, Arak University of Medical Science, Arak, Iran.
| | | | | | | |
Collapse
|
49
|
Abstract
Granulomatous interstitial nephritis is a rare extraintestinal manifestation of Crohn disease that has been described previously in 4 patients. We report a 23-year-old man with a history of Crohn disease since age 6 years who was admitted to the hospital for weight loss, fever, and bloody diarrhea in the midst of a recent flare up during the past 2 months. Investigations revealed anemia, high erythrocyte sedimentation rate, high C-reactive protein level, and an elevated serum creatinine level. Histopathologic examination of tissue specimens obtained at renal biopsy demonstrated granulomatous interstitial nephritis. Crohn disease needs to be in the differential diagnosis of granulomatous interstitial nephritis and can be a manifestation of drug allergy or the Crohn disease itself.
Collapse
Affiliation(s)
- Robert B. Colvin
- From the Departments of Pathology (Drs Colvin and Taheri) and Nephrology (Dr Traum), Massachusetts General Hospital, Harvard Medical School, Boston; the Isfahan Kidney Disease Research Center, Isfahan, Iran (Dr Taheri); and the Department of Pathology, School of Medicine (Drs Taheri and Jafari), and the Faculty of Medicine (Dolatkhah), Isfahan University of Medical Sciences, Isfahan, Iran
| | - Avram Z. Traum
- From the Departments of Pathology (Drs Colvin and Taheri) and Nephrology (Dr Traum), Massachusetts General Hospital, Harvard Medical School, Boston; the Isfahan Kidney Disease Research Center, Isfahan, Iran (Dr Taheri); and the Department of Pathology, School of Medicine (Drs Taheri and Jafari), and the Faculty of Medicine (Dolatkhah), Isfahan University of Medical Sciences, Isfahan, Iran
| | - Diana Taheri
- From the Departments of Pathology (Drs Colvin and Taheri) and Nephrology (Dr Traum), Massachusetts General Hospital, Harvard Medical School, Boston; the Isfahan Kidney Disease Research Center, Isfahan, Iran (Dr Taheri); and the Department of Pathology, School of Medicine (Drs Taheri and Jafari), and the Faculty of Medicine (Dolatkhah), Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohsen Jafari
- From the Departments of Pathology (Drs Colvin and Taheri) and Nephrology (Dr Traum), Massachusetts General Hospital, Harvard Medical School, Boston; the Isfahan Kidney Disease Research Center, Isfahan, Iran (Dr Taheri); and the Department of Pathology, School of Medicine (Drs Taheri and Jafari), and the Faculty of Medicine (Dolatkhah), Isfahan University of Medical Sciences, Isfahan, Iran
| | - Shahaboddin Dolatkhah
- From the Departments of Pathology (Drs Colvin and Taheri) and Nephrology (Dr Traum), Massachusetts General Hospital, Harvard Medical School, Boston; the Isfahan Kidney Disease Research Center, Isfahan, Iran (Dr Taheri); and the Department of Pathology, School of Medicine (Drs Taheri and Jafari), and the Faculty of Medicine (Dolatkhah), Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
50
|
Fesharakizadeh M, Taheri D, Dolatkhah S, Wexner SD. Postoperative ileus in colorectal surgery: is there any difference between laparoscopic and open surgery? Gastroenterol Rep (Oxf) 2013; 1:138-43. [PMID: 24759819 PMCID: PMC3938009 DOI: 10.1093/gastro/got008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Background: Postoperative ileus is a major complication of patients undergoing abdominal surgery. The purpose of this study was to determine the effects of operative time and the method of surgery on postoperative ileus. Methods: After institutional review board approval, 121 patients were studied in two groups. Group 1 consisted of 86 patients with colorectal cancers and Group 2 included 35 patients with diverticulitis. Various surgical procedures were performed in both groups. In all patients, the nasogastric (NG) tube was removed after termination of surgery. Clear liquids were offered commencing on the first postoperative day, followed by a regular diet as tolerated. GI-1 was the postoperative time to toleration of clear liquids, whereas GI-2 was the postoperative time to first bowel movement or flatus and toleration of a regular diet. Statistical analysis was performed using a linear regression model by disease with the first bowel movement or flatus as the dependent variable and operative time and category as explanatory variables. Results: Vomiting after oral feeding occurred in 18 (20.9%) patients with cancer and in 7 (20.0%) patients with diverticular disease. An NG tube was reinserted in 13 (15.1%) patients in the cancer group and in 3 (8.6%) patients in the diverticular disease group. In patients with cancer, the duration of operation was associated with GI-2 (P = 0.011), whereas in patients with diverticulitis, the duration of operation was associated with GI-1 (P = 0.001) and GI-2 (P = 0.044). In the diverticulitis group, a significant relationship was found between GI-2 and operative category (P = 0.03). Conclusion: Longer operations led to more prolonged postoperative ileus after both laparoscopy and laparotomy, regardless of malignant or benign pathology. In anticipation of and/or following longer operations, surgeons should consider measures to shorten postoperative ileus.
Collapse
Affiliation(s)
- Mehdi Fesharakizadeh
- Faculty of Medicine, Islamic Azad University, Najaf Abad Branch, Isfahan, Iran, Department of Colorectal Surgery, Cleveland Clinic Florida, Weston, Florida, USA, Department of Pathology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran and Medical student, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | | | | |
Collapse
|